1. Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity
- Author
-
Francesco Del Giudice, Angelo Porreca, Daniela Terracciano, Daniele Romagnoli, Alessandro Sciarra, Gabriele Antonini, Paolo Corsi, Katie Palmer, Alessandro Del Rosso, Marco Giampaoli, Matteo Ferro, Ottavio De Cobelli, Daniele D'Agostino, Giuseppe Lucarelli, Martina Maggi, Gian Maria Busetto, Ettore De Berardinis, Busetto, Gian Maria, Del Giudice, Francesco, Maggi, Martina, Antonini, Gabriele, D'Agostino, Daniele, Romagnoli, Daniele, Del Rosso, Alessandro, Giampaoli, Marco, Corsi, Paolo, Palmer, Katie, Ferro, Matteo, Lucarelli, Giuseppe, Terracciano, Daniela, De Cobelli, Ottavio, Sciarra, Alessandro, De Berardinis, Ettore, and Porreca, Angelo
- Subjects
5α-reductase inhibitor ,Male ,Vascular Endothelial Growth Factor A ,Aging ,medicine.medical_specialty ,Enucleation ,Placebo-controlled study ,Urology ,Blood Loss, Surgical ,Prostatic Hyperplasia ,5α-reductase inhibitors ,dutasteride ,holmium laser enucleation of the prostate ,microvascular density ,vascular endothelial growth factor ,Lasers, Solid-State ,Hematocrit ,Placebo ,chemistry.chemical_compound ,Holmium ,5-alpha Reductase Inhibitors ,Double-Blind Method ,Prostate ,medicine ,Humans ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Cell Biology ,Perioperative ,Middle Aged ,Dutasteride ,medicine.anatomical_structure ,Treatment Outcome ,chemistry ,Prostate surgery ,business ,Research Paper - Abstract
Five α-reductase inhibitors (5ARIs) are able to reduce prostate volume and are a useful treatment for reducing perioperative bleeding during prostate surgery. Holmium laser enucleation of the prostate (HoLEP) is an effective surgical technique for the definitive cure of benign prostate enlargement. We investigated whether pretreatment with dutasteride before HoLEP could reduce intraoperative bleeding. A total of 402 patients were included in this double-blind placebo-controlled trial to receive daily 0.5 mg of dutasteride or placebo over 8 weeks before HoLEP. Vascular endothelial growth factor (VEGF) and microvascular density (MVD) were evaluated. Analysis was also stratified according to prostate volume (
- Published
- 2019